Deutsche Märkte geschlossen

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
42,63+1,37 (+3,32%)
Börsenschluss: 4:00PM EDT

uniQure N.V.

Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
http://www.uniqure.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter248

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Matthew Craig KapustaCEO, CFO & Exec. Director908,63k459,12k1972
Dr. Alexander E. Kuta Ph.D.Exec. VP of Operations610,61k2,42M1960
Dr. Robert Gut M.D., Ph.D.Exec. Director747,11kN/A1965
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyN/AN/AN/A
Mr. Christian KlemtChief Accounting OfficerN/AN/A1973
Mr. David CervenyChief Legal Officer, Gen. Counsel & Sec.N/AN/A1967
Ms. Maria E. CantorChief Communications OfficerN/AN/A1968
Dr. Tamara Tugal Ph.D., MBABus. Devel. DirectorN/AN/AN/A
Mr. James BradyChief HR OfficerN/AN/AN/A
Mr. Jonathan GarenChief Bus. OfficerN/AN/A1966
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.s ISS Governance QualityScore, Stand 6. Oktober 2020, lautet 2. Die grundlegenden Scores sind Audit: 2, Vorstand: 4, Shareholderrechte: 3, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.